Informed by these mechanistic studies, successful phase 3 clinical trials have led to a second generation MC4R agonist being licensed in many countries for the treatment of several monogenic disorders (POMC, PCSK1, LEPR deficiencies and Bardet-Biedl Syndrome (BBS)) [29,30]. This evidence concerns the gene LEPR and Bardet-Biedl syndrome.